Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Cytochrome P-450 CYP3A"" wg kryterium: Temat


Tytuł:
Physiologically-based pharmacokinetic model of sparsentan to evaluate drug-drug interaction potential.
Autorzy:
Patel NK; Simcyp Division, Certara UK Limited, Sheffield, UK.
Chen KF; Simcyp Division, Certara UK Limited, Sheffield, UK.
Chen SC; Formerly Travere Therapeutics, Inc., San Diego, California, USA.
Liu K; Travere Therapeutics, Inc., San Diego, California, USA.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2024 Feb; Vol. 13 (2), pp. 317-329. Date of Electronic Publication: 2023 Dec 02.
Typ publikacji:
Journal Article
MeSH Terms:
Cytochrome P-450 CYP3A*/metabolism
Models, Biological*
Spiro Compounds*
Sulfonamides*
Adult ; Humans ; Cytochrome P-450 CYP3A Inhibitors/pharmacology ; Drug Interactions
Czasopismo naukowe
Tytuł:
Assessment of CYP3A-mediated drug interaction via cytokine (IL-6) elevation for mosunetuzumab using physiologically-based pharmacokinetic modeling.
Autorzy:
Chen Y; Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California, USA.
Ma F; Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California, USA.
Jones N; Clinical Science, Genentech, Inc., South San Francisco, California, USA.
Deng R; Clinical Pharmacology, Genentech, Inc., South San Francisco, California, USA.
Li C; Clinical Pharmacology, Genentech, Inc., South San Francisco, California, USA.
Li CC; Clinical Pharmacology, Genentech, Inc., South San Francisco, California, USA.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2024 Feb; Vol. 13 (2), pp. 234-246. Date of Electronic Publication: 2023 Dec 04.
Typ publikacji:
Journal Article
MeSH Terms:
Cytochrome P-450 CYP3A*/metabolism
Antineoplastic Agents*
Humans ; Interleukin-6 ; Cytokines ; Drug Interactions ; Cytochrome P-450 CYP3A Inhibitors/pharmacokinetics ; Models, Biological
Czasopismo naukowe
Tytuł:
A comprehensive evaluation in clinic and physiologically-based pharmacokinetic modeling and simulation to confirm lack of cytochrome P450-mediated drug-drug interaction potential for pomotrelvir.
Autorzy:
Yang Z; Pardes Biosciences, Inc., Carlsbad, California, USA.
Rioux N; Certara, Princeton, New Jersey, USA.
Vincent L; Certara, Princeton, New Jersey, USA.
Jones HM; Certara, Princeton, New Jersey, USA.
Cha D; Pardes Biosciences, Inc., Carlsbad, California, USA.
Plummer A; Pardes Biosciences, Inc., Carlsbad, California, USA.
Wilfret D; Pardes Biosciences, Inc., Carlsbad, California, USA.
Kearney BP; Pardes Biosciences, Inc., Carlsbad, California, USA.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Oct; Vol. 12 (10), pp. 1553-1564. Date of Electronic Publication: 2023 Aug 30.
Typ publikacji:
Journal Article
MeSH Terms:
Cytochrome P-450 CYP3A*
Hepatitis C, Chronic*
Humans ; Female ; Antiviral Agents/pharmacology ; Cytochrome P-450 Enzyme System ; Drug Interactions ; Protein Isoforms ; Models, Biological ; Cytochrome P-450 CYP3A Inhibitors/pharmacology ; Computer Simulation
Czasopismo naukowe
Tytuł:
Physiologically-based pharmacokinetic modeling of quinidine to establish a CYP3A4, P-gp, and CYP2D6 drug-drug-gene interaction network.
Autorzy:
Feick D; Clinical Pharmacy, Saarland University, Saarbrücken, Germany.
Rüdesheim S; Clinical Pharmacy, Saarland University, Saarbrücken, Germany.; Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany.
Marok FZ; Clinical Pharmacy, Saarland University, Saarbrücken, Germany.
Selzer D; Clinical Pharmacy, Saarland University, Saarbrücken, Germany.
Loer HLH; Clinical Pharmacy, Saarland University, Saarbrücken, Germany.
Teutonico D; Translational Medicine & Early Development, Sanofi-Aventis R&D, Chilly-Mazarin, France.
Frechen S; Bayer AG, Pharmaceuticals, Research & Development, Systems Pharmacology & Medicine, Leverkusen, Germany.
van der Lee M; Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
Moes DJAR; Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
Swen JJ; Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
Schwab M; Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany.; Departments of Clinical Pharmacology, Pharmacy and Biochemistry, University of Tübingen, Tübingen, Germany.; Cluster of Excellence iFIT (EXC2180) 'Image-guided and Functionally Instructed Tumor Therapies', University of Tübingen, Tübingen, Germany.
Lehr T; Clinical Pharmacy, Saarland University, Saarbrücken, Germany.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Aug; Vol. 12 (8), pp. 1143-1156. Date of Electronic Publication: 2023 May 23.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Cytochrome P-450 CYP2D6*/genetics
Cytochrome P-450 CYP2D6*/metabolism
Cytochrome P-450 CYP3A*/genetics
Cytochrome P-450 CYP3A*/metabolism
Humans ; Quinidine ; ATP Binding Cassette Transporter, Subfamily B, Member 1/genetics ; Drug Interactions ; Models, Biological ; Cytochrome P-450 CYP3A Inhibitors/pharmacokinetics
Czasopismo naukowe
Tytuł:
Tiered approach to evaluate the CYP3A victim and perpetrator drug-drug interaction potential for vonoprazan using PBPK modeling and clinical data to inform labeling.
Autorzy:
Mulford DJ; Phathom Pharmaceuticals, Inc., Buffalo Grove, Illinois, USA.
Ramsden D; Takeda Pharmaceuticals, Cambridge, Massachusetts, USA.
Zhang L; Takeda Pharmaceuticals, Cambridge, Massachusetts, USA.
Michon I; Certara, Sheffield, UK.
Leifke E; Phathom Pharmaceuticals, Inc., Buffalo Grove, Illinois, USA.
Smith N; Phathom Pharmaceuticals, Inc., Buffalo Grove, Illinois, USA.
Jones HM; Certara, Sheffield, UK.
Scarpignato C; United Campus of Malta, Msida, Malta.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Apr; Vol. 12 (4), pp. 532-544. Date of Electronic Publication: 2023 Mar 10.
Typ publikacji:
Journal Article
MeSH Terms:
Cytochrome P-450 CYP3A Inhibitors*/pharmacokinetics
Cytochrome P-450 CYP3A Inducers*/pharmacokinetics
Humans ; Midazolam/pharmacokinetics ; Cytochrome P-450 CYP3A/metabolism ; Drug Interactions ; Models, Biological
Czasopismo naukowe
Tytuł:
Pharmacokinetic Interaction of Chiglitazar with CYP3A4 Inducer or Inhibitor: An Open-Label, Sequential Crossover, Self-Control, 3-Period Study in Healthy Chinese Volunteers.
Autorzy:
Yuan F; Department of Clinical Pharmacology, Zhongshan Hospital, Fudan University, Shanghai, China.
Li J; Department of Clinical Pharmacology, Zhongshan Hospital, Fudan University, Shanghai, China.
Li X; Department of Clinical Pharmacology, Zhongshan Hospital, Fudan University, Shanghai, China.
Li H; Department of Clinical Pharmacology, Zhongshan Hospital, Fudan University, Shanghai, China.
Chen W; Department of Clinical Pharmacology, Zhongshan Hospital, Fudan University, Shanghai, China.
Yang M; Department of Clinical Pharmacology, Zhongshan Hospital, Fudan University, Shanghai, China.
Chen H; Department of Clinical Pharmacology, Zhongshan Hospital, Fudan University, Shanghai, China.
Sheng L; Department of Clinical Pharmacology, Zhongshan Hospital, Fudan University, Shanghai, China.
Liu C; Department of Clinical Pharmacology, Zhongshan Hospital, Fudan University, Shanghai, China.
Wu Y; Department of Clinical Pharmacology, Zhongshan Hospital, Fudan University, Shanghai, China.
Xu H; Department of Clinical Pharmacology, Zhongshan Hospital, Fudan University, Shanghai, China.
Pokaż więcej
Źródło:
Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2023 Feb; Vol. 12 (2), pp. 168-174. Date of Electronic Publication: 2022 Dec 30.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Cytochrome P-450 CYP3A Inducers*/adverse effects
Cytochrome P-450 CYP3A Inhibitors*/pharmacology
Humans ; Rifampin ; Healthy Volunteers ; East Asian People ; Cytochrome P-450 Enzyme Inducers ; Cytochrome P-450 CYP3A/metabolism
Czasopismo naukowe
Tytuł:
Physiologically-based pharmacokinetic modeling for primary metabolites of CYP3A and P-glycoprotein inhibitors in drug-drug interactions: Should we assume the free drug hypothesis?
Autorzy:
Yamazaki S; Drug Metabolism & Pharmacokinetics, Janssen Research & Development, LLC, San Diego, California, USA.
Evers R; Drug Metabolism & Pharmacokinetics, Janssen Research & Development, LLC, Spring House, Pennsylvania, USA.
De Zwart L; Drug Metabolism & Pharmacokinetics, Janssen Research & Development, Beerse, Belgium.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Jan; Vol. 12 (1), pp. 8-12. Date of Electronic Publication: 2022 Nov 11.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Cytochrome P-450 CYP3A*/metabolism
Cytochrome P-450 CYP3A Inhibitors*/pharmacokinetics
Humans ; Rifampin/pharmacokinetics ; ATP Binding Cassette Transporter, Subfamily B ; Drug Interactions ; Models, Biological ; Cytochrome P-450 CYP3A Inducers/pharmacokinetics
Czasopismo naukowe
Tytuł:
PBPK perspective on alternative CYP3A4 inducers for rifampin.
Autorzy:
Chen KF; Certara UK Limited (Simcyp Division), Sheffield, UK.
Jones HM; Certara UK Limited (Simcyp Division), Sheffield, UK.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2022 Dec; Vol. 11 (12), pp. 1543-1546. Date of Electronic Publication: 2022 Sep 22.
Typ publikacji:
Journal Article
MeSH Terms:
Cytochrome P-450 CYP3A Inducers*
Rifampin*/pharmacology
Humans ; Cytochrome P-450 CYP3A Inhibitors ; Cytochrome P-450 CYP3A ; Drug Interactions
Czasopismo naukowe
Tytuł:
Drug-Drug Interactions With the Hepatitis B Virus Capsid Assembly Modulator JNJ-56136379 (Bersacapavir).
Autorzy:
Vandenbossche J; Janssen Pharmaceutica NV, Beerse, Belgium.
Yogaratnam J; Janssen Research & Development, South San Francisco, California, USA.
Hillewaert V; Janssen Pharmaceutica NV, Beerse, Belgium.
Rasschaert F; Janssen Pharmaceutica NV, Beerse, Belgium.
Talloen W; Janssen Pharmaceutica NV, Beerse, Belgium.
Biewenga J; Janssen Pharmaceutica NV, Beerse, Belgium.
Snoeys J; Janssen Pharmaceutica NV, Beerse, Belgium.
Kakuda TN; Janssen Research & Development, South San Francisco, California, USA.
Palmer M; Janssen Research & Development, Spring House, Pennsylvania, USA.
Nangosyah J; Janssen Pharmaceutica NV, Beerse, Belgium.
Biermer M; Janssen Pharmaceutica NV, Beerse, Belgium.
Pokaż więcej
Źródło:
Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2022 Dec; Vol. 11 (12), pp. 1419-1429. Date of Electronic Publication: 2022 Sep 05.
Typ publikacji:
Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Cytochrome P-450 CYP3A Inhibitors*/pharmacology
Hepatitis B virus*/metabolism
Adult ; Female ; Humans ; Antiviral Agents/adverse effects ; Capsid/metabolism ; Cytochrome P-450 CYP3A/metabolism ; Drug Interactions ; Ethinyl Estradiol/pharmacology ; Itraconazole/pharmacokinetics ; Midazolam/pharmacokinetics
Czasopismo naukowe
Tytuł:
Drug-Drug Interaction Studies to Evaluate the Effect of Inhibition of UGT1A1 and CYP3A4 and Induction of CYP3A4 on the Pharmacokinetics of Tropifexor in Healthy Subjects.
Autorzy:
Chen J; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
Stringer R; Novartis Institutes for BioMedical Research, PK Sciences, Basel, Switzerland.
Shah B; Novartis Institutes for Biomedical Research, East Hanover, New Jersey, USA.
Gu J; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, USA.
Zhang Y; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
Hackling M; Novartis Institutes for Biomedical Research, East Hanover, New Jersey, USA.
Prince W; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, USA.
Woessner R; Novartis Institutes for BioMedical Research, PK Sciences, Basel, Switzerland.
Pokaż więcej
Źródło:
Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2022 Nov; Vol. 11 (11), pp. 1253-1263. Date of Electronic Publication: 2022 Aug 12.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Cytochrome P-450 CYP3A*/metabolism
Itraconazole*
Humans ; Cytochrome P-450 CYP3A Inhibitors/pharmacology ; Drug Interactions ; Healthy Volunteers ; Rifampin
Czasopismo naukowe
Tytuł:
Alternatives to rifampicin: A review and perspectives on the choice of strong CYP3A inducers for clinical drug-drug interaction studies.
Autorzy:
Bolleddula J; Quantitative Pharmacology, EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts, USA.
Gopalakrishnan S; Merck KGaA, Darmstadt, Germany.
Hu P; Quantitative Pharmacology, EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts, USA.
Dong J; Quantitative Pharmacology, EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts, USA.
Venkatakrishnan K; Quantitative Pharmacology, EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts, USA.
Pokaż więcej
Źródło:
Clinical and translational science [Clin Transl Sci] 2022 Sep; Vol. 15 (9), pp. 2075-2095. Date of Electronic Publication: 2022 Jul 25.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Cytochrome P-450 CYP3A Inducers*/pharmacology
Rifampin*/pharmacology
Cytochrome P-450 CYP3A ; Cytochrome P-450 CYP3A Inhibitors ; Drug Interactions ; Humans
Czasopismo naukowe
Tytuł:
A Phase 1 Pharmacokinetic Drug Interaction Study of Belumosudil Coadministered With CYP3A4 Inhibitors and Inducers and Proton Pump Inhibitors.
Autorzy:
Schueller O; Kadmon Corporation, LLC, Cambridge, Massachusetts, USA.
Willson A; Quotient Sciences, Nottingham, UK.
Singh N; Quotient Sciences, Nottingham, UK.
Lohmer L; Nuventra, LLC, Durham, North Carolina, USA.
Alabanza A; Nuventra, LLC, Durham, North Carolina, USA.
Patel J; Kadmon Corporation, LLC, Cambridge, Massachusetts, USA.
Pokaż więcej
Źródło:
Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2022 Jul; Vol. 11 (7), pp. 795-806. Date of Electronic Publication: 2022 Mar 01.
Typ publikacji:
Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Cytochrome P-450 CYP3A Inhibitors*/pharmacology
Proton Pump Inhibitors*/pharmacology
Acetamides ; Cytochrome P-450 CYP3A/metabolism ; Cytochrome P-450 CYP3A Inducers/pharmacology ; Cytochrome P-450 Enzyme Inducers ; Drug Interactions ; Humans ; Itraconazole ; Omeprazole/pharmacology ; Protein Kinases ; Rabeprazole/pharmacology ; Rifampin
Czasopismo naukowe
Tytuł:
Pharmacokinetics of asciminib in the presence of CYP3A or P-gp inhibitors, CYP3A inducers, and acid-reducing agents.
Autorzy:
Hoch M; Novartis Institutes for BioMedical Research, Basel, Switzerland.
Huth F; Novartis Institutes for BioMedical Research, Basel, Switzerland.
Sato M; Novartis Pharma K.K., Novartis Institutes for Biomedical Research, Tokyo, Japan.
Sengupta T; Novartis Healthcare Pvt. Ltd., Hyderabad, India.
Quinlan M; Novartis Pharmaceuticals, East Hanover, New Jersey, USA.
Dodd S; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA.
Kapoor S; Novartis Pharmaceuticals, East Hanover, New Jersey, USA.
Hourcade-Potelleret F; Novartis Institutes for BioMedical Research, Basel, Switzerland.
Pokaż więcej
Źródło:
Clinical and translational science [Clin Transl Sci] 2022 Jul; Vol. 15 (7), pp. 1698-1712. Date of Electronic Publication: 2022 May 26.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Cyclodextrins*
Cytochrome P-450 CYP3A Inducers*/pharmacokinetics
ATP Binding Cassette Transporter, Subfamily B, Member 1 ; Cytochrome P-450 CYP3A/metabolism ; Cytochrome P-450 CYP3A Inhibitors/pharmacology ; Drug Interactions ; Healthy Volunteers ; Humans ; Itraconazole/pharmacology ; Niacinamide/analogs & derivatives ; Pyrazoles ; Reducing Agents
Czasopismo naukowe
Tytuł:
Evaluation of drug-drug interaction potential for pemigatinib using physiologically based pharmacokinetic modeling.
Autorzy:
Ji T; Incyte Research Institute, Wilmington, Delaware, USA.
Chen X; Incyte Research Institute, Wilmington, Delaware, USA.
Yeleswaram S; Incyte Research Institute, Wilmington, Delaware, USA.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2022 Jul; Vol. 11 (7), pp. 894-905. Date of Electronic Publication: 2022 May 23.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Cytochrome P-450 CYP3A Inhibitors*/pharmacology
Rifampin*/pharmacokinetics
Cytochrome P-450 CYP3A/metabolism ; Cytochrome P-450 CYP3A Inducers/pharmacology ; Drug Interactions ; Humans ; Itraconazole/pharmacokinetics ; Models, Biological ; Morpholines ; Pyrimidines ; Pyrroles
Czasopismo naukowe
Tytuł:
Equilibrium landscape of ingress/egress channels and gating residues of the Cytochrome P450 3A4.
Autorzy:
Ackad EM; Department of Physics, Southern Illinois University Edwardsville, Edwardsville, IL, United States of America.
Biggers L; Department of Internal Medicine at UT Southwestern Medical Center, Dallas, TX, United States of America.
Meister M; University of Illinois College of Medicine, Chicago, IL, United States of America.
Kontoyianni M; Department of Pharmaceutical Sciences, Southern Illinois University Edwardsville, Edwardsville, IL, United States of America.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2024 Mar 18; Vol. 19 (3), pp. e0298424. Date of Electronic Publication: 2024 Mar 18 (Print Publication: 2024).
Typ publikacji:
Journal Article
MeSH Terms:
Cytochrome P-450 CYP3A*/metabolism
Cytochrome P-450 Enzyme System*/metabolism
Drug Interactions
Czasopismo naukowe
Tytuł:
Synthesis of mono Cytochrome P450 in a modified CHO-CPR cell-free protein production platform.
Autorzy:
Knauer JF; Fraunhofer Project Group PZ-Syn of the Fraunhofer Institute for Cell Therapy and Immunology, Branch Bioanalytics and Bioprocesses (IZI-BB), Potsdam, Germany.; Fraunhofer Institute for Cell Therapy and Immunology (IZI), Branch Bioanalytics and Bioprocesses (IZI-BB), Potsdam, Germany.; Freie Universität Berlin, Institute of Chemistry and Biochemistry - Biochemistry, Berlin, Germany.
Schulz C; Fraunhofer Project Group PZ-Syn of the Fraunhofer Institute for Cell Therapy and Immunology, Branch Bioanalytics and Bioprocesses (IZI-BB), Potsdam, Germany.; Institute of Biotechnology, Brandenburg University of Technology Cottbus-Senftenberg, Senftenberg, Germany.
Zemella A; Fraunhofer Institute for Cell Therapy and Immunology (IZI), Branch Bioanalytics and Bioprocesses (IZI-BB), Potsdam, Germany. .
Wüstenhagen DA; Fraunhofer Institute for Cell Therapy and Immunology (IZI), Branch Bioanalytics and Bioprocesses (IZI-BB), Potsdam, Germany.
Walter RM; Fraunhofer Institute for Cell Therapy and Immunology (IZI), Branch Bioanalytics and Bioprocesses (IZI-BB), Potsdam, Germany.; Institute of Biotechnology, Technische Universität Berlin, Gustav-Meyer-Allee 25, 13355, Berlin, Germany.
Küpper JH; Institute of Biotechnology, Brandenburg University of Technology Cottbus-Senftenberg, Senftenberg, Germany.
Kubick S; Fraunhofer Institute for Cell Therapy and Immunology (IZI), Branch Bioanalytics and Bioprocesses (IZI-BB), Potsdam, Germany.; Freie Universität Berlin, Institute of Chemistry and Biochemistry - Biochemistry, Berlin, Germany.; Faculty of Health Sciences, Joint Faculty of the Brandenburg University of Technology Cottbus -Senftenberg, the Brandenburg Medical School Theodor Fontane and the University of Potsdam, Potsdam, Germany.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Jan 13; Vol. 14 (1), pp. 1271. Date of Electronic Publication: 2024 Jan 13.
Typ publikacji:
Journal Article
MeSH Terms:
Cytochrome P-450 Enzyme System*/metabolism
Cytochrome P-450 CYP3A*/metabolism
Animals ; Humans ; NADP ; Microsomes/metabolism ; Luciferases ; Microsomes, Liver/metabolism ; Mammals/metabolism
Czasopismo naukowe
Tytuł:
Study of the ketohexokinase inhibitor PF-06835919 as a clinical cytochrome P450 3A inducer: Integrated use of oral midazolam and liquid biopsy.
Autorzy:
Qiu R; Pfizer Inc, Cambridge, Massachusetts, USA.
Fonseca K; Pfizer Inc, Cambridge, Massachusetts, USA.
Bergman A; Pfizer Inc, Cambridge, Massachusetts, USA.
Lin J; Pfizer Inc, Groton, Connecticut, USA.
Tess D; Pfizer Inc, Cambridge, Massachusetts, USA.
Newman L; Flinders University, Adelaide, South Australia, Australia.
Fahmy A; Flinders University, Adelaide, South Australia, Australia.
Useckaite Z; Flinders University, Adelaide, South Australia, Australia.
Rowland A; Flinders University, Adelaide, South Australia, Australia.
Vourvahis M; Pfizer Inc, New York, New York, USA.
Rodrigues D; Pfizer Inc, Groton, Connecticut, USA.
Pokaż więcej
Źródło:
Clinical and translational science [Clin Transl Sci] 2024 Jan; Vol. 17 (1), pp. e13644. Date of Electronic Publication: 2023 Dec 18.
Typ publikacji:
Journal Article
MeSH Terms:
Midazolam*/pharmacokinetics
Cytochrome P-450 CYP3A*/metabolism
Humans ; Proteomics ; Pharmaceutical Preparations ; Liquid Biopsy ; Drug Interactions ; Administration, Oral
Czasopismo naukowe
Tytuł:
Predictability of human exposure by human-CYP3A4-transgenic mouse models: A meta-analysis.
Autorzy:
Damoiseaux D; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Schinkel AH; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Beijnen JH; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
Huitema ADR; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Pharmacology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Dorlo TPC; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Pharmacy, Uppsala University, Uppsala, Sweden.
Pokaż więcej
Źródło:
Clinical and translational science [Clin Transl Sci] 2024 Jan; Vol. 17 (1), pp. e13668. Date of Electronic Publication: 2023 Dec 01.
Typ publikacji:
Meta-Analysis; Journal Article; Review
MeSH Terms:
Cytochrome P-450 CYP3A*/metabolism
Cytochrome P-450 Enzyme System*/metabolism
Humans ; Mice ; Animals ; Mice, Transgenic ; Models, Animal ; Drug Interactions
Czasopismo naukowe
Tytuł:
Toward improved predictions of pharmacokinetics of transported drugs in hepatic impairment: Insights from the extended clearance model.
Autorzy:
Storelli F; Department of Pharmaceutics, University of Washington, Seattle, Washington, USA.
Ladumor MK; Department of Pharmaceutics, University of Washington, Seattle, Washington, USA.
Liang X; Drug Metabolism, Gilead Sciences Inc., Foster City, California, USA.
Lai Y; Drug Metabolism, Gilead Sciences Inc., Foster City, California, USA.
Chothe PP; Global Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc., Lexington, Massachusetts, USA.
Enogieru OJ; Pharmacokinetics & Drug Metabolism, Amgen, South San Francisco, California, USA.
Evers R; Preclinical Sciences and Translational Safety, Janssen Research & Development, LLC, Spring House, Pennsylvania, USA.
Unadkat JD; Department of Pharmaceutics, University of Washington, Seattle, Washington, USA.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2024 Jan; Vol. 13 (1), pp. 118-131. Date of Electronic Publication: 2023 Oct 20.
Typ publikacji:
Journal Article
MeSH Terms:
Cytochrome P-450 CYP3A*/metabolism
Organic Anion Transporters*/metabolism
Humans ; Liver/metabolism ; Biological Transport ; Rosuvastatin Calcium ; Drug Interactions
Czasopismo naukowe
Tytuł:
Investigation of CYP3A induction by PF-05251749 in early clinical development: comparison of linear slope physiologically based pharmacokinetic prediction and biomarker response.
Autorzy:
Lin J; Medicine Design Pharmacokinetics, Pharmacodynamics, and Metabolism, Worldwide Research, Development and Medical, Pfizer Inc., Groton, Connecticut, USA.
Gaudreault F; Clinical Pharmacology, Early Clinical Development, Worldwide Research, Development and Medical, Pfizer Inc., Cambridge, Massachusetts, USA.
Johnson N; Medicine Design Pharmacokinetics, Pharmacodynamics, and Metabolism, Worldwide Research, Development and Medical, Pfizer Inc., Groton, Connecticut, USA.
Lin Z; Medicine Design Pharmacokinetics, Pharmacodynamics, and Metabolism, Worldwide Research, Development and Medical, Pfizer Inc., Groton, Connecticut, USA.
Nouri P; Clinical Assay Group, Global Product Development, Pfizer Inc., Cambridge, Massachusetts, USA.
Goosen TC; Medicine Design Pharmacokinetics, Pharmacodynamics, and Metabolism, Worldwide Research, Development and Medical, Pfizer Inc., Groton, Connecticut, USA.
Sawant-Basak A; Clinical Pharmacology, Early Clinical Development, Worldwide Research, Development and Medical, Pfizer Inc., Cambridge, Massachusetts, USA.
Pokaż więcej
Źródło:
Clinical and translational science [Clin Transl Sci] 2022 Sep; Vol. 15 (9), pp. 2184-2194. Date of Electronic Publication: 2022 Jul 02.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Cytochrome P-450 CYP3A*/genetics
Midazolam*/pharmacokinetics
Biomarkers ; Cytochrome P-450 CYP3A Inducers ; Drug Interactions ; Humans ; Models, Biological
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies